U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07691697) titled 'PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer' on June 28.
Brief Summary: PSMA-OLIGO-PRO is a multicenter ambispective observational real-world registry evaluating outcomes after PSMA PET-guided progression-directed radiotherapy for oligoprogressive prostate cancer. The registry includes retrospectively identified patients treated before June 26, 2026 and prospectively enrolled patients from June 26, 2026 onward.
Eligible patients have metastatic hormone-sensitive or castration-resistant prostate cancer, are receiving active systemic therapy, and develop a limited number of new or regrowing ...